BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 16296776)

  • 1. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.
    Andrade F; Rafael D; Videira M; Ferreira D; Sosnik A; Sarmento B
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1816-27. PubMed ID: 23932923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Powder specific active dispersion for generation of pharmaceutical aerosols.
    Crowder T; Hickey A
    Int J Pharm; 2006 Dec; 327(1-2):65-72. PubMed ID: 16930884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration.
    Crowder TM
    Expert Opin Drug Deliv; 2005 May; 2(3):579-85. PubMed ID: 16296776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metered-dose inhalers, dry powder inhalers, and transitions.
    Fink JB
    Respir Care; 2000 Jun; 45(6):623-35. PubMed ID: 10894455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry powder inhalers (DPIs)--a review of device reliability and innovation.
    Islam N; Gladki E
    Int J Pharm; 2008 Aug; 360(1-2):1-11. PubMed ID: 18583072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary drug delivery by powder aerosols.
    Yang MY; Chan JG; Chan HK
    J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active and intelligent inhaler device development.
    Tobyn M; Staniforth JN; Morton D; Harmer Q; Newton ME
    Int J Pharm; 2004 Jun; 277(1-2):31-7. PubMed ID: 15158967
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.